Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDavis, Ian D-
dc.contributor.authorQuirk, Juliet-
dc.contributor.authorMorris, Leone-
dc.contributor.authorSeddon, Lauren-
dc.contributor.authorTai, Tsin Yee-
dc.contributor.authorWhitty, Genevieve-
dc.contributor.authorCavicchiolo, Tina-
dc.contributor.authorEbert, Lisa-
dc.contributor.authorJackson, Heather-
dc.contributor.authorBrowning, Judy-
dc.contributor.authorMacGregor, Duncan-
dc.contributor.authorWittke, Frederick-
dc.contributor.authorWinkels, Gregor-
dc.contributor.authorAlex, Regina-
dc.contributor.authorMiloradovic, Lena-
dc.contributor.authorMaraskovsky, Eugene-
dc.contributor.authorChen, Weisan-
dc.contributor.authorCebon, Jonathan S-
dc.identifier.citationImmunotherapy 2017; 9(3): 249-259en_US
dc.description.abstractPilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. PATIENTS & METHODS: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS®plus, with initial depletion of CD1c+ B cells followed by positive selection of CD1c+ PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. RESULTS: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells did not correlate with outcomes. One patient had a long lasting complete remission. CONCLUSION: This method was feasible and safe but was minimally immunogenic.en_US
dc.subjectISCOMATRIX™ adjuvanten_US
dc.subjectClinical trialen_US
dc.subjectDendritic cellsen_US
dc.titleA pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvanten_US
dc.typeJournal Articleen_US
dc.identifier.affiliationLudwig Institute for Cancer Research, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medical Oncology, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationMonash University Eastern Health Clinical School, Box Hill, Victoria, Australiaen_US
dc.identifier.affiliationEastern Health, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Anatomical Pathology, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationMiltenyi Biotec, Germanyen_US
dc.identifier.affiliationCSL Limited, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Victoria, Australiaen_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen_US
dc.type.studyortrialClinical Trialen_US
dc.type.austinJournal Articleen_US
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.cerifentitytypePublications- Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 7, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.